Skip to main content
Diasorin logo

Diasorin — Investor Relations & Filings

Ticker · DIA ISIN · IT0003492391 LEI · 8156002878BDF0EE4348 XMIL Manufacturing
Open in API
Filings indexed 817 across all filing types
Latest filing 2022-09-14 Legal Proceedings Report
Country IT Italy
Listing XMIL DIA

About Diasorin

https://diasoringroup.com/en

Diasorin is a global leader in the In Vitro Diagnostic (IVD) field, developing, producing, and marketing reagent kits for laboratory diagnostics. The company specializes in immunodiagnostics and molecular diagnostics. Its immunodiagnostics technology is based on detecting antibodies and antigens in fluid samples to identify diseases or measure physiological markers. The molecular diagnostics division provides flexible tools using targeted and multiplex technologies to detect pathogens in biological specimens. Since 2021, Diasorin has also been active in the Life Science business, offering platforms for biomedical research, clinical diagnostics, and drug discovery. Through its product lines, such as the LIAISON® family of analyzers and assays, the company aims to empower healthcare providers with actionable information to improve patient care, enable faster triage, and reduce unnecessary antibiotic use.

Recent filings

Filing Released Lang Actions
DIASORIN SIMPLEXA™ COVID-19 TEST RECEIVED U.S. FDA 510(K) CLEARANCE
Legal Proceedings Report Classification · 99% confidence The document is a formal announcement dated September 14, 2022, originating from DiaSorin, detailing that they have received U.S. FDA 510(k) clearance for their Simplexa™ COVID-19 Direct kit. The structure, including 'Informazione Regolamentata' headers, a specific object description, and a concluding section with contact information and company boilerplate, strongly suggests a regulatory disclosure or press release regarding a significant operational/product event. Since this is an announcement about receiving regulatory clearance for a product, it is not a full financial report (10-K, IR), an earnings release (ER), or a management discussion (MDA). It is a specific operational update. Given the options, this type of announcement—a material event disclosure that isn't strictly financial, management change, or capital activity—best fits under the general 'Regulatory Filings' (RNS) category, as it is a formal notification to the market about regulatory progress, or potentially a general press release that doesn't fit other specific categories. It is not a proxy statement (DEF 14A), a dividend notice (DIV), or a director dealing report (DIRS). RNS is the most appropriate fallback for significant, non-standard regulatory/operational news.
2022-09-14 English
DiaSorin riceve l'approvazione 510k per il test Simplexa COVID
Regulatory Filings Classification · 95% confidence The document is a formal press release dated September 14, 2022, originating from DiaSorin, announcing that it has received 510(k) clearance from the US FDA for its Simplexa™ COVID-19 Direct molecular test. The content focuses on a specific regulatory achievement and its implications for product availability and performance. This type of announcement, detailing a significant operational or regulatory milestone rather than periodic financial results (like 10-K or ER) or management changes, fits best under the general category of Regulatory Filings (RNS) or potentially a specific announcement if one were available. Since the core purpose is to disseminate news about a regulatory clearance (FDA 510(k)), and it is not a full financial report, a proxy statement, or an earnings release, RNS (Regulatory Filings) serves as the most appropriate general classification for non-standard, material announcements. The document length (6506 chars) is substantial enough that it is the announcement itself, not just a brief notice of publication (which would suggest RPA).
2022-09-14 Italian
Report on the treasury shares buy-back plan of DiaSorin S.p.A. - Period 06/09/2022- 12/09/2022
Transaction in Own Shares Classification · 99% confidence The document is explicitly titled "WEEKLY REPORT ON THE TREASURY SHARES BUY-BACK PLAN OF DIASORIN S.P.A." and details the number of shares purchased, the consideration, and the resulting treasury share holding as of September 12, 2022. This content directly relates to the company's actions regarding its own shares (share repurchase). This aligns perfectly with the definition for 'Transaction in Own Shares' (Code: POS). Although it is a report, the key action described is the repurchase, not just an announcement of a report's publication (which would be RPA/RNS).
2022-09-12 English
Informativa sul programma di acquisto di azioni proprie di DiaSorin S.p.A. - Periodo 06/09/2022-12/09/2022
Transaction in Own Shares Classification · 99% confidence The document is titled "INFORMATIVA SETTIMANALE SUL PROGRAMMA DI ACQUISTO DI AZIONI PROPRIE DI DIASORIN S.P.A." (Weekly Information on the Share Buyback Program of DiaSorin S.p.A.). It details the number of own shares purchased during the period 06/09/2022-12/09/2022, including daily transaction tables and total consideration. This directly corresponds to the definition of a report detailing the company buying back or selling its own shares. This matches the definition for Transaction in Own Shares (POS). It is not a general regulatory filing (RNS) because it is highly specific, nor is it a Director's Dealing (DIRS) as it concerns the company itself buying back shares, not individual directors trading their personal holdings.
2022-09-12 Italian
Report on the treasury shares buy-back plan of DiaSorin S.p.A. - Period 30/08/2022- 05/09/2022
Transaction in Own Shares Classification · 98% confidence The document is titled 'WEEKLY REPORT ON THE TREASURY SHARES BUY-BACK PLAN OF DIASORIN S.P.A.' and details the number of shares purchased, the consideration, and the resulting treasury share holding as of September 5, 2022. This activity—the company buying back its own shares—directly corresponds to the definition of 'Transaction in Own Shares' (POS). Although it is a weekly report, the core subject matter is the share repurchase program, making POS the most specific classification over a general Regulatory Filing (RNS) or Report Publication Announcement (RPA), especially given the substantial document length suggesting detailed content rather than just an announcement of attachment.
2022-09-05 English
Informativa sul programma di acquisto di azioni proprie di DiaSorin S.p.A. - Periodo 30/08/2022 -05/09/2022
Transaction in Own Shares Classification · 98% confidence The document is titled "INFORMATIVA SETTIMANALE SUL PROGRAMMA DI ACQUISTO DI AZIONI PROPRIE DI DIASORIN S.P.A." (Weekly Information on the Share Buyback Program of DiaSorin S.p.A.) and details the number of shares purchased, the total consideration, and provides a daily breakdown of transactions for the period 30/08/2022 - 05/09/2022. This directly relates to the company repurchasing its own shares. According to the definitions, this corresponds to 'Transaction in Own Shares' (Code: POS). Although it is a detailed report, it is a specific regulatory disclosure about share transactions, not a general annual report (10-K) or an interim report (IR).
2022-09-05 Italian

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.